Price
No data yet.
Social Signal Score
Analyst Ratings
26 analystsRevenue
$213.47MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Dinesh V. Patel
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 141
- Beta
- 1.79
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 124.02
Financials
Revenue
$213.47M+2331.1%Net Income
$162.85MEBITDA
$165.11MFree Cash Flow
$218.88MEPS (diluted)
$2.29Shares Outstanding (diluted)
71.01M+737.0%Operating Expenses
$54.71MCash & Debt
$782.58MReturn of Capital
$0.00Revenue by Segment (annual)
$15.30MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $46.02M | $-130.15M | $-2.05 |
| 2024 | $434.43M | $275.19M | $4.47 |
| 2023 | $60.00M | $-78.95M | $-1.39 |
| 2022 | $26.58M | $-127.39M | $-2.52 |
| 2021 | $27.36M | $-125.55M | $-2.65 |
| 2020 | $28.63M | $-66.15M | $-1.92 |
| 2019 | $231.0K | $-77.19M | $-2.98 |
| 2018 | $30.93M | $-38.92M | $-1.74 |
| 2017 | $20.06M | $-36.96M | $-2.09 |
| 2016 | $0.00 | $-37.18M | $-5.72 |
| 2015 | $0.00 | $-14.86M | $-2.52 |
| 2014 | $0.00 | $-11.07M | $-1.88 |
Valuation
PTGXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70+0.00%Social Signal Score
Mentions (12)
- Newsseekingalpha.com·26d ago·Positive
Protagonist Therapeutics, Inc. (PTGX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Protagonist Therapeutics, Inc. (PTGX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
View source ↗ - News (RSS)yahoo·29d ago·Negative
Protagonist (PTGX) Swings To A Profit As Two Drugs Near Blockbuster Status
View source ↗ - News (RSS)yahoo·31d ago·Negative
MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model?
View source ↗ - Newsaccessnewswire.com·34d ago·Neutral
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in September 2026 NEWARK, CA / ACCESS Newswire / September 2, 2026 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D.
View source ↗ - News (RSS)seekingalpha·35d ago·Positive
Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia Vera Transcript
View source ↗ - Newsseekingalpha.com·35d ago·Positive
Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia Vera Transcript Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia Vera Transcript
View source ↗ - News (RSS)seekingalpha·35d ago·Neutral
Protagonist Therapeutics, Inc. (PTGX) Discusses FDA Approval of Mimrylo for Erythrocytosis in Polycythemia Vera - Slideshow
View source ↗ - Newsmarketbeat.com·35d ago·Negative
Protagonist Wins FDA Approval for MIMRYLO in Rare Blood Cancer Treatment Protagonist Therapeutics NASDAQ: PTGX said the U.S. Food and Drug Administration has approved rusfertide, to be marketed as MIMRYLO, for the treatment of erythrocytosis in adults with polycythemia vera, or PV.
View source ↗ - News (RSS)investing·38d ago·Negative
Protagonist Therapeutics receives FDA approval for polycythemia vera drug
View source ↗ - Newsaccessnewswire.com·38d ago·Negative
… Future Milestones Investor call to be held Monday, August 31st at 8:30 am ET NEWARK, CA / ACCESS Newswire / August 28, 2026 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") announced today that Takeda received U.S. Food and Drug Administration (FDA) approval for MIMRYLO (rusfertide), a subcutaneously delivered first-in-class hepcidin mimetic peptide for the treatment of erythrocytosis in adults with polycythemia vera (PV). MIMRYLO is the first and only hepcidin mi…
View source ↗ - Newsaccessnewswire.com·48d ago·Negative
Protagonist Therapeutics Reports Granting of Inducement Awards NEWARK, CA / ACCESS Newswire / August 18, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on August 17, 2026, it granted inducement awards to two recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 20…
View source ↗ - Newsseekingalpha.com·55d ago·Positive
Protagonist Therapeutics: "Strong Buy" ICOTYDE FDA Approval And PN-881 Advancement Protagonist Therapeutics (PTGX) maintains a "Strong Buy" rating, driven by FDA approval of ICOTYDE for moderate-to-severe plaque psoriasis and strong partnership economics. Company is advancing rusfertide for polycythemia vera, with FDA Priority Review decision expected August 2026 and substantial milestone and royalty potential from Takeda. Development pipeline includes oral IL-17 antagonist PN-881 for psoriasis
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $2.43 per share
Typical surprise +2.7% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$2.29 vs $2.23beat
- Tue, May 5$0.05 vs $-0.65beat
- Wed, Feb 25$-0.69 vs $-0.53miss
- Thu, Nov 6$-0.62 vs $-0.59miss
- Wed, Aug 6$-0.55 vs $-0.53miss
- Tue, May 6$-0.19 vs $-0.50beat
Estimates and results for PTGX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PTGX officers and directors.
- Bought
- —
- Sold
- $86.8m
0 trades
33 trades
- Ali Asifsold
- Ali Asifsold
- Patel Dinesh V Ph Dsold
- Patel Dinesh V Ph Dsold
- Patel Dinesh V Ph Dsold
- Patel Dinesh V Ph Dsold
- Patel Dinesh V Ph Dsold
- Waddill William D.sold
67 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PTGX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.